Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.006... ohhh so close 58% ...? Scotty we need more power!
Yes Sir,PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past, and some new ones...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made, it’s not the inability to see the future, but to act on it ;)
25 Years..., Velcro that’s right...it took Velcro 25 years to hit the world theatre & not look back $$$, from the 1st day the inventor’s dog got covered with burrs (I wonder what he was thinking ? “Gee maybe I could attach tools to my workbench wall with those or make a product ????”, or going out on a limb here! “I wonder if just some day we could make it easier for a women to do a noninvasive reliable breast exam with a technological superior
attachment to her breast???? I just wonder !)
Tech.—reverse psychology ????, like “too bad” I just won $1 million in lotto...(CBM world revenue 1% women)
Tony amazing, nice find ... it’s sad when your smart phone calculator using only 1% of the women in the world times $225 gives you an error calculation because the annual sales number is too BIG ! (i’d have to go back and look at my old post, but I believe the Cyrcadia Breast Monitor iTBra annual revenue per Rob was going to be around $225 for 12 annual examinations uploaded)
I agree as well, just didn’t want to hype that route again @ exp of sounding like a pumper...
(But, it’s clear that we appear to off all had this feeling ?!?! Great entry point for a smart product tech co., to say
hey look at us...!)
Great open, good 3 month chart...Tony thnx for the article
Reminds me of Cytosorbents (as posted previously), no FDA, but selling outside USA then Covid & wham FDA emergency approval last year...LLBO only needs one point of light & our cap could easily be @ .16 cents/ share
cap adjusted for OS vs Cyto...? But, that’s only my opinion, the market as always will decide?
( I think there is something, more important than believing: Action!
W. Clement Stone )
Great, recent find
Tonyb2232 post excerpt from his posted article —
:)
29/01/2021
“AI did better than the radiologist with a 5% reduction in false negatives.
Wearables are another innovation, at the crossroads of the Internet of Things and AI. For example, we already have innovative solutions such as a bra that detects breast cancer. The American laboratory Cyrcadia proposes a prototype named iTbra™. This brassiere vest allows the detection of breast cancer in its early stages with at least as much sensitivity as a mammogram.3
Composed of two intelligent breast patches placed in a bra, this wearable technology identifies temperature changes in breast tissue. A self-learning predictive analysis AI is used to identify and classify abnormalities in breast tissue. In case of abnormalities, the system will alert the patient to go to a physician to perform the appropriate imaging examinations. The initial results of this invention are promising and certification is underway.
If this system is so efficient, why not use the same technology with a connected undergarment that would detect genital cancers? Or a T-shirt that would detect the presence of tumors? It sounds like science fiction, but the field of wearable technology is making great strides.”
Confirm prev post—
Testing—2020 Nov Article— “Until now, “twenty-six clinics” have adopted the use of the device for the first screening.”
“The Cyrcadia device comes with a sensor-brassiere and soft- ware. The software is helpful to read the information gath- ered by the sensors. A medical practitioner must instruct the patient the usage procedures on their first time and the individual may then carry their test by themselves at the comfort of their own homes.”
Source:
Early Detection and Screening of Breast Cancer: An Investigation Case on Mammography Risks in Mauritians
Nov 2020
(Very interesting article above “”Testing in 26 clinics””... “Testing in 26 clinics” well per below article CBM (iTBra) was to launch in Asia 2020, seems like a lot more going on than they’re letting us now!?!?. Maybe Covid has not slowed things, but increased activity! Interestingly enough, I flytech who had invested in Cyrcadia Health in 2018, mentioned they were trying to incorporate as much AI in all of their customer institutions, Who better than to have a partner like iFlytech?)
Arnie, would u check with JH & see if he’ll comment on CBM (iTBra) in
26 Asian clinics for 1st screening 2020, per my post #31402 2-12-20
Cytosorbents, Biel, LLBO, etc., all day trades back in 08-09, “made good money $5 dollars a day”, no made much more than that...several million LLBO shares I parked in the vault!
(I sold my 21,000 shares Cytosorbents, never got FDA approval til Covid FDA emergency use, but their Sepsis filter was sold overseas prior to that, sounds like another stock I know...? Oh LLBO)
Testing—2020 Nov Article— “Until now, “twenty-six clinics” have adopted the use of the device for the first screening.”
“The Cyrcadia device comes with a sensor-brassiere and soft- ware. The software is helpful to read the information gath- ered by the sensors. A medical practitioner must instruct the patient the usage procedures on their first time and the individual may then carry their test by themselves at the comfort of their own homes.”
Source:
Early Detection and Screening of Breast Cancer: An Investigation Case on Mammography Risks in Mauritians
Nov 2020
(Very interesting article above “”Testing in 26 clinics””... “Testing in 26 clinics” well per below article CBM (iTBra) was to launch in Asia 2020
...WTF... seems like a lot more going on than they’re letting us now!?!?. Maybe Covid has not slowed things, but increased activity! Interestingly enough, I flytech who had invested in Cyrcadia Health in 2018, mentioned they were trying to incorporate as much AI in all of their customer institutions, Who better than to have a partner like iFlytech?) Tic toc tic ....toc...The Crap dice seem to be slowing down ...
Cyrcadia Asia Ltd
I'm Rob Royea, CEO of Cyrcadia which is launching breast cancer wearable.—
“I'm the CEO and co-founder of Cyrcadia Asia, Ltd. which is launching the world's 1st wearable metabolic breast cancer screening technology.
2020 launch:”“Cyrcadia is developing and marketing a device and software that monitors for biometric changes that correlate
to breast cancer. Cyrcadia's technology is based on wearable sensor patches that are placed under a
woman’s own garments and worn during the normal day's activity. The sensor data results processed through Cyrcadia’s artificial intelligence (AI) lab can be automatically communicated to the patient, her physician and insurance company.
Cyrcadia will deliver peace of mind to women with an smart wearable device that can automatically communicate to a physician in the case of an alert. Upon launch in 2020, Cyrcadia will ensure mass population screenings through it's current and upcoming clinical and commercial partnerships.”
Source below-
https://www.f6s.com/cyrcadiaasialtd
*Also from 26 clinic article—excerpt:
“In “2020”, huge Tech Giants are making millions off mobile health applications by using sensors to track their bodily movement. With the innovations in technology, people are having access to personalized health tools that can be used at their convenience. Nowadays, there are millions of small business mushrooming online providing online doctor, disease diagnosis, drug reference, and many more. As everything is moving towards digitalization and due to its numerous benefits, it will also be valuable if cancer screening is conducted more safely.”
Akshita.Parbhudayal@gmail.com
Source article—
Early Detection and Screening of Breast Cancer: An Investigation Case on Mammography Risks in Mauritians
:) :)
FDA Class1 is the target, trials are still advancing, yes it is the CBM (iTBra) & do to Covid Cyrcadia Health is running a lean office Consultant work force if u will ???
(FDA Class 1 would be mega)!
Yes Sir,PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Yes Sir,PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Yes Sir,PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Lityx Co. customer is (Cyrcadia Health)
Cancer Detection with Sensor Data
Cyrcadia Health
June 2020:
“Lityx was selected because of their reputation for scalable business solutions. The LityxIQ platform will continue to support our needs as we introduce new applications that will increase our need for big data.”
– Dave Wertzberger, Marketing and Risk Management Director, Cyrcadia Health
June 2020. Is (Ed Wertzberger on Cyrcadia Health Board coincidence?)
—The Results
40+ algorithms and technical settings in bake-off with no programming
Modeling completed in small fraction of the time compared to previous attempts to perform cancer detection with sensor data
Ability to automatically deploy models to incoming sensor big data streams
“Cyrcadia Health previously invested in analytics systems to support their modeling and big data needs. However, their original system was built using a package that was neither flexible nor scalable to meet the growing needs for visualization and big data management. Prior engagements with specialized teams were not able to consistently resolve the important issues of modeling accuracy, scalability of technology, and handling of big data from streaming sensor technologies.”
https://cdn.featuredcustomers.com/CustomerCaseStudy.document/cancer-detection-sensor-data-cyrcadia.pdf
Lityx customer Cyrcadia Health
Lityx Co. customer is (Cyrcadia Health)
Cancer Detection with Sensor Data
Cyrcadia Health
June 2020:
“Lityx was selected because of their reputation for scalable business solutions. The LityxIQ platform will continue to support our needs as we introduce new applications that will increase our need for big data.”
– Dave Wertzberger, Marketing and Risk Management Director, Cyrcadia Health
June 2020. Is (Ed Wertzberger on Cyrcadia Health Board coincidence?)
—The Results
40+ algorithms and technical settings in bake-off with no programming
Modeling completed in small fraction of the time compared to previous attempts to perform cancer detection with sensor data
Ability to automatically deploy models to incoming sensor big data streams
“Cyrcadia Health previously invested in analytics systems to support their modeling and big data needs. However, their original system was built using a package that was neither flexible nor scalable to meet the growing needs for visualization and big data management. Prior engagements with specialized teams were not able to consistently resolve the important issues of modeling accuracy, scalability of technology, and handling of big data from streaming sensor technologies.”
https://cdn.featuredcustomers.com/CustomerCaseStudy.document/cancer-detection-sensor-data-cyrcadia.pdf
Lityx customer Cyrcadia Health
Data processing center is a work in progress, as posted before (As Mentioned before, she’s been setting the lab up for the past three years getting ready for CBM data input and AI-ANN results)
Vinitha Sree
Director, “Analytics Core Lab”@ Cyrcadia Health, Inc.
Skills:
Cancer Research, Clinical Decision Support, Materials Science, Computer Aided Diagnosis, Matlab, Biomedical Engineering, Clinical Research, Image Processing, Life Sciences, Atherosclerosis, Data Mining, Signal Processing, Bioinformatics, Breast Imaging, Cancer, Diabetes Management, Research, Healthcare Management, Machine Learning, SPSS, Pattern Recognition
“Computer Methods and Programs in Biomedicine
Volume 197, December 2020, 105758
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device
Vinitha Sree”
Jim Homes Cyrcadia-
Jim’s pretty easy to catch up with, find him at the Office 1325 Airmotive Way Suite 175 L Reno, NV.,
home Xxx xxxxx xxxxxxx, Reno, NV., & occasionally out sailing Lake Tahoe which he has a passion for.
Very personable individual.
FDA advances landmark policy changes to modernize mammography services and improve their quality
Today’s proposed amendments are part of the agency’s broader commitment to supporting “new innovations” and methods to prevent, detect and treat cancer. We are dedicated to working across the agency and with stakeholders to provide patients with tools and information to fight breast cancer effectively.”4-2019
Cisco 1/7 articles, Cisco world broadcast
Newsroom.Cisco.com/feature-content
Dist: 76,0000 employees + Network
Cisco very aware of Cyrcadia Breast Monitor & International data collection center(as I posted many moons ago)!
***********
article 1/7 article
Cisco Worldwide Network
Technology gains accuracy in detecting cancers
by Stephanie Chan (Stephanie Ellen Chan is the Editorial and Video Producer for Cisco's technology news site
Cisco Network)
June 01, 2018
“Since the debut of the film last year, Cyrcadia Health has been hard at work on new AI algorithms to improve their product. A blog in May reports that the team's software scientists have made new discoveries that can further help cancer patients and doctors. One of these discoveries includes the ability to locate abnormal lesions so that doctors know where to start advanced therapies. Another accomplishment is that wear time of the device can now be as little as two hours.”
****************
article 2/7 article
Cisco Feature Story
Tech wearable transforms the fight against breast cancer
by Sophia Lin (Sophia Lin is a Social Media Strategist for Cisco Global Communications)
May 24, 2017
The Network Cisco
Tech wearable transforms the fight against breast cancer
Rob Royea, CEO of Cyrcadia Health Asia, helped develop an IoT wearable to detect breast cancer. He shares his thoughts on transforming the healthcare industry with technology and his role in DETECTED.
About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime. One businessman is betting technology can drastically bring down those numbers. Rob Royea has 20 plus years of experience in clinical based diagnosis for conditions including cancer under his belt. He knew it was time to change the focus from breast cancer diagnosis to early detection. His weapon- an extraordinary wearable called the iTBra, which can detect cancer at its earliest possible stages. The story, is the focus of a powerful new documentary short called Detected. Cisco funded the film, which just debuted at the Boston Independent Film Festival in April, and will screen at Ahrya Fine Arts by Laemmle in Beverly Hills on June 5th.
I talked to Royea about the technology, and his journey to get the bra to market.
Sophia Lin: What is the iTBra? How does it work?
Rob Royea: The iTBra is a wearable device that is worn under a woman's garments that can detect the earliest signs of invasive cancer. Sensors that sit on the body under a women's own garment can sense metabolic change over time through thermodynamic assessment. The data collected by the sensors are then transmitted to a core lab where we use artificial intelligence or predictive analytics in the cloud to determine the results. The results are then sent back to the patients or to the physician and the insurance company. Patients can easily read the results that basically tell them "you're fine" or "call your doctor."
SL: What led you to the iTBra?
RR: The concept of the iTBra was well originated before I was involved. The board of directors of the company was looking for a CEO who could determine how to develop a scalable the technology that wasn't yet scalable and while ensuring accuracy of screening for the mass population. What I really saw in the technology, was the ability to get it out to the mass population but more importantly be able to get early in the diagnosis. When it comes to screening and monitoring, the ability to find cancers earlier is all about saving lives.
SL: How will the iTBra affect breast cancer awareness?
RR: Women really want to know about their breast health. It's not about a cancer alarm but self-awareness. Women want know they are actually leading a healthy life. The reassurance and the calm that comes to them is what we're looking to supply through the iTBra. It's changing from a monthly screening that you're suggested to do, to now actually having a smart technology that can reassure you that your breast health is fine. We want to provide encouragement of getting screened through a social context. It'll encourage sisters, families and friends to screen.
SL: Can you give us an update on what stage the bra is in now?
RR: We've gone through a US clinical trial where we've been able to drop the wear time from 48 hours to two hours and increase the accuracy from 74.5% to over 80%. At the end of this year, we plan on releasing a commercial product in Asia that will allow people to pair the iTBra with a smart phone app for results. In the US, we have an FDA Class 2 clearance and working toward a FDA Class 1 clearance which would enable over the counter product delivery.
SL: How do you think IoT wearables will transform the healthcare industry?
RR: It's a radical shift in time of diagnosis. It goes from being hospital or clinic based to population health. We now have the ability to monitor women as they go about their daily activities, rather than waiting from 8-10 years for a tumor to finally be visible on a mammography or ultrasound. It's going to be a radical shift in the paradigm of location and timing of diagnosis.
See also: Breast cancer detection in a bra: IoT's powerful life-saving potential
SL: What was it like having a camera crew following you around for the filming of Detected?
RR: It was crazy! There were cameras all around all the time. What was great, was that women would walk up and tell you exactly what they felt. They wanted to talk about breast health. We got a great deal of input from women as to how we should deliver the product and what it should do for women in the process.
SL: What was your favorite part of filming?
RR: Being able to tell the story for the first time about a fitness device migrating to a wellness technology. We're looking at something that's a sustainable healthcare product that someone could wear beyond breast cancer. There's the possibility that someone will monitor themselves in the future almost as second nature.
SL: What is the one you thing you want people to take away after watching the documentary?
RR: Technology is evolving to the point that we can wear sensors and to know more about our ongoing health condition. More importantly, welcome health monitoring through intelligent technologies. Having a sensor on you doesn't mean that you're monitoring for bad habits, monitoring can save your life! Think about the future of healthcare wearables and understand why it's important for better outcomes and better family time.
****************
Cisco 3/7 article
National Cancer Survivors Day is on June 4th. Follow the conversation at Detected Movie and #DetectedMovie. The best gadgets and wearables promoting women's health
by Stephanie Chan (Stephanie Ellen Chan is the Editorial and Video Producer for Cisco's technology news site The Network.)
May 18, 2017
The best gadgets and wearables promoting women's health
From smart sports bras to glucose monitoring devices, see how new technology is innovating healthcare this National Women's Health Week.
Whether with apps, gadgets, or anything in between, technology has made incredible advances with helping the human body. As we celebrate this month's National Women's Health Week, let's take a look at some of the latest technology helping women maintain their health and wellness.
Digital Trends reports the latest in Apple Watch rumors, writing that the Apple Watch 3 may include sensors that can monitor blood glucose levels. With diabetes research being a big area of interest for the company, Apple may be revolutionizing glucose monitoring for the millions of people suffering from diabetes.
Exercise and lifestyle company Adidas recently launched their All Day fitness app for women. Gadgets and Wearables writes that this app offers meal plans, workouts customized for the user, sleep aids, and mindfulness regimen. This app also lets users in on fitness advice from experts, as well as curating personal music playlists for workouts. Unique in its mix of content within the app, All Day is available for users on both iOS and Android.
Women who run can now benefit from gadget-less cardio time with OMsignal's new smart sports bra. Sports Illustrated reports that the "OMbra" is outfitted with both heart and breathing sensors so that women don't have to be bogged down by extra technology.
The documentary Detected explores a similar style of bra technology—a smart IT Bra that can help detect breast cancer. The innovative piece of Internet of Things technology is highlighted in the new film, which Cisco and Ironbound Films partnered to bring to life. You can catch a screening of this documentary June 5, 2017 in Beverly Hills, California. To RSVP, please check here.
*****************
Cisco -3/7 article
New wearables revolutionize detection of health issues
by Stephanie Chan
April 17, 2017
(Also mentions iTBra)
**************
Cisco- 4/7 article
Maciej Kranz
(Vice President and General Manager
Corporate Strategic Innovation Group)
With Early Cancer Detection, IoT Saves More than Money—It Can Save Lives
Maciej Kranz
This week at the Internet of Things World Forum, we’ve been hearing a lot about the transformational value of the Internet of Things (IoT) across many industries – manufacturing, transportation, agriculture, smart cities, retail, and finance. So many new solutions are on display that help organizations either save or make money. But in healthcare, IoT can actually do more than that, it has the potential to save lives.
You may be thinking, “Of course—wearables, remote monitoring, performance tracking. These concepts have been around for a while now.” And yes, these technologies and devices are already working to improve health and fitness. One recent development, however, has really captured my attention because of its potential to help with early detection of breast cancer. That’s the idea behind the connected bra—dubbed the” iTBra” by its inventor, Rob Royea, CEO of Cyrcadia Health. With embedded temperature sensors, this new kind of wearable technology tracks changes in temperature in breast tissue over time. It uses machine learning and predictive analytics to identify and classify abnormal patterns that could indicate early stage breast cancer. And women will be glad to know that they just need to wear the iTBra for 2 to 12 hours once a month as they go about their daily activities—there’s no painful squashing or prodding or radiation involved.
The iTBra fits comfortably under virtually any normal bra and can transmit results to a smartphone.
This technology marks a vast improvement over traditional mammography, which generally doesn’t detect the presence of cancer until it is in Stage 3 or 4. It is also much more accurate than mammography, which produces a high number of both false-positive and false-negative results. Currently, more than 70 percent of biopsies that are done as a result of a suspicious mammogram turn out to be non-cancerous tissue. And in women with dense breast tissue, mammograms miss the presence of cancer more than 50 percent of the time. Because the iTBra relies on different detection technology, its false negative rate has so far been 17.3 percent for all tissue types—an improvement for all women, but especially for those with dense tissue.
Connected bra technology is many times more accurate than mammography in detecting the presence of cancer.
“Detected” is a new short documentary film sponsored by Cisco that shows the development of the iTBra, from the seed of an idea to its acceptance for clinical trials. The power of this documentary is not only about the ground-breaking idea itself, but also about the innovation process. I have been a keen observer and practitioner of innovation and co-innovation for years, and therefore I appreciate how the film realistically depicts the entrepreneurial struggle—a great idea, some false starts, some wrong turns. We also see Rob Royea’s grit and determination as he doggedly persists through obstacles, builds a coalition of the willing across the globe, and spreads his enthusiasm and passion about the project to people around him.
Rob Royea, right, discusses circuitry design with a development partner in Israel.
The connected bra idea is already so powerful by itself; but this is just a start. As Rob Royea says in the film, “What if you can screen three million people in Asia in a single year? What if you can create this mega database through the Internet, that can analyze how some people, versus others, have cancer?“
This is where IoT, in combination with the cloud, machine learning, and analytics capabilities, can truly become transformative. Mammograms—and the radiology expertise needed to interpret their results—are still out of reach for billions of women, especially in poor countries. Now, with inexpensive, non-invasive technology, you can now screen millions of women who have never had access to screening before. And in the process you can gather massive amounts of anonymized data that can help us research and hopefully better understand what factors contribute to a woman getting breast cancer in the first place. In a world where more than half-a-million women die from breast cancer each year, such connected IoT solutions can not only help cancer detection, but also cancer prevention.
The connected bra is just one of the reasons IoT in healthcare is especially exciting to me. Combined with rapid advances in areas ranging from bio- and DNA engineering, to robotics, prosthetics, and remote care, IoT is poised to dramatically improve many aspects of our lives—enhancing not only how long, but also how well we live. This is why I believe it is so important to rally behind entrepreneurs such as Rob Royea. We should support the efforts of current innovators and create incentives and programs for new ventures in the IoT healthcare field. Because in healthcare, the stakes are not just about efficiency or productivity; they’re about our lives.
*******************
Cisco -article 5/7
Detected: How IoT, Cloud, Wearables, and AI show hope in the fight against breast cancer
May 24, 2017
****************
Cisco article 6/7
AI creates breakthroughs in Alzheimer's and beyond
by Stephanie Chan
January 29, 2018
****************
Twitter Cisco post AI artificial intelligence is the future
Nov 1, 2018. Cisco @ Cisco
Analytics and automation are fueling an IT operations revolution. Are you ready? cs.co/6013Dhqft
—-Tweet: Cyrcadia Health Cyrcadia Asia create cloud based Core Lab Div Cyrcadia user base grows, it has the potential to be the world lgst database of breast prevention /treatment Data from the iTBra is communicated directly to the Cyrcadia's Core Lab for analysis by PC /smartphone app
***********************
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Tic toc tic toc ..,.
Cisco 1/7 articles, Cisco world broadcast
Newsroom.Cisco.com/feature-content
Dist: 76,0000 employees + Network
Cisco very aware of Cyrcadia Breast Monitor & International data collection center(as I posted many moons ago)!
***********
article 1/7 article
Cisco Worldwide Network
Technology gains accuracy in detecting cancers
by Stephanie Chan (Stephanie Ellen Chan is the Editorial and Video Producer for Cisco's technology news site
Cisco Network)
June 01, 2018
“Since the debut of the film last year, Cyrcadia Health has been hard at work on new AI algorithms to improve their product. A blog in May reports that the team's software scientists have made new discoveries that can further help cancer patients and doctors. One of these discoveries includes the ability to locate abnormal lesions so that doctors know where to start advanced therapies. Another accomplishment is that wear time of the device can now be as little as two hours.”
****************
article 2/7 article
Cisco Feature Story
Tech wearable transforms the fight against breast cancer
by Sophia Lin (Sophia Lin is a Social Media Strategist for Cisco Global Communications)
May 24, 2017
The Network Cisco
Tech wearable transforms the fight against breast cancer
Rob Royea, CEO of Cyrcadia Health Asia, helped develop an IoT wearable to detect breast cancer. He shares his thoughts on transforming the healthcare industry with technology and his role in DETECTED.
About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime. One businessman is betting technology can drastically bring down those numbers. Rob Royea has 20 plus years of experience in clinical based diagnosis for conditions including cancer under his belt. He knew it was time to change the focus from breast cancer diagnosis to early detection. His weapon- an extraordinary wearable called the iTBra, which can detect cancer at its earliest possible stages. The story, is the focus of a powerful new documentary short called Detected. Cisco funded the film, which just debuted at the Boston Independent Film Festival in April, and will screen at Ahrya Fine Arts by Laemmle in Beverly Hills on June 5th.
I talked to Royea about the technology, and his journey to get the bra to market.
Sophia Lin: What is the iTBra? How does it work?
Rob Royea: The iTBra is a wearable device that is worn under a woman's garments that can detect the earliest signs of invasive cancer. Sensors that sit on the body under a women's own garment can sense metabolic change over time through thermodynamic assessment. The data collected by the sensors are then transmitted to a core lab where we use artificial intelligence or predictive analytics in the cloud to determine the results. The results are then sent back to the patients or to the physician and the insurance company. Patients can easily read the results that basically tell them "you're fine" or "call your doctor."
SL: What led you to the iTBra?
RR: The concept of the iTBra was well originated before I was involved. The board of directors of the company was looking for a CEO who could determine how to develop a scalable the technology that wasn't yet scalable and while ensuring accuracy of screening for the mass population. What I really saw in the technology, was the ability to get it out to the mass population but more importantly be able to get early in the diagnosis. When it comes to screening and monitoring, the ability to find cancers earlier is all about saving lives.
SL: How will the iTBra affect breast cancer awareness?
RR: Women really want to know about their breast health. It's not about a cancer alarm but self-awareness. Women want know they are actually leading a healthy life. The reassurance and the calm that comes to them is what we're looking to supply through the iTBra. It's changing from a monthly screening that you're suggested to do, to now actually having a smart technology that can reassure you that your breast health is fine. We want to provide encouragement of getting screened through a social context. It'll encourage sisters, families and friends to screen.
SL: Can you give us an update on what stage the bra is in now?
RR: We've gone through a US clinical trial where we've been able to drop the wear time from 48 hours to two hours and increase the accuracy from 74.5% to over 80%. At the end of this year, we plan on releasing a commercial product in Asia that will allow people to pair the iTBra with a smart phone app for results. In the US, we have an FDA Class 2 clearance and working toward a FDA Class 1 clearance which would enable over the counter product delivery.
SL: How do you think IoT wearables will transform the healthcare industry?
RR: It's a radical shift in time of diagnosis. It goes from being hospital or clinic based to population health. We now have the ability to monitor women as they go about their daily activities, rather than waiting from 8-10 years for a tumor to finally be visible on a mammography or ultrasound. It's going to be a radical shift in the paradigm of location and timing of diagnosis.
See also: Breast cancer detection in a bra: IoT's powerful life-saving potential
SL: What was it like having a camera crew following you around for the filming of Detected?
RR: It was crazy! There were cameras all around all the time. What was great, was that women would walk up and tell you exactly what they felt. They wanted to talk about breast health. We got a great deal of input from women as to how we should deliver the product and what it should do for women in the process.
SL: What was your favorite part of filming?
RR: Being able to tell the story for the first time about a fitness device migrating to a wellness technology. We're looking at something that's a sustainable healthcare product that someone could wear beyond breast cancer. There's the possibility that someone will monitor themselves in the future almost as second nature.
SL: What is the one you thing you want people to take away after watching the documentary?
RR: Technology is evolving to the point that we can wear sensors and to know more about our ongoing health condition. More importantly, welcome health monitoring through intelligent technologies. Having a sensor on you doesn't mean that you're monitoring for bad habits, monitoring can save your life! Think about the future of healthcare wearables and understand why it's important for better outcomes and better family time.
****************
Cisco 3/7 article
National Cancer Survivors Day is on June 4th. Follow the conversation at Detected Movie and #DetectedMovie. The best gadgets and wearables promoting women's health
by Stephanie Chan (Stephanie Ellen Chan is the Editorial and Video Producer for Cisco's technology news site The Network.)
May 18, 2017
The best gadgets and wearables promoting women's health
From smart sports bras to glucose monitoring devices, see how new technology is innovating healthcare this National Women's Health Week.
Whether with apps, gadgets, or anything in between, technology has made incredible advances with helping the human body. As we celebrate this month's National Women's Health Week, let's take a look at some of the latest technology helping women maintain their health and wellness.
Digital Trends reports the latest in Apple Watch rumors, writing that the Apple Watch 3 may include sensors that can monitor blood glucose levels. With diabetes research being a big area of interest for the company, Apple may be revolutionizing glucose monitoring for the millions of people suffering from diabetes.
Exercise and lifestyle company Adidas recently launched their All Day fitness app for women. Gadgets and Wearables writes that this app offers meal plans, workouts customized for the user, sleep aids, and mindfulness regimen. This app also lets users in on fitness advice from experts, as well as curating personal music playlists for workouts. Unique in its mix of content within the app, All Day is available for users on both iOS and Android.
Women who run can now benefit from gadget-less cardio time with OMsignal's new smart sports bra. Sports Illustrated reports that the "OMbra" is outfitted with both heart and breathing sensors so that women don't have to be bogged down by extra technology.
The documentary Detected explores a similar style of bra technology—a smart IT Bra that can help detect breast cancer. The innovative piece of Internet of Things technology is highlighted in the new film, which Cisco and Ironbound Films partnered to bring to life. You can catch a screening of this documentary June 5, 2017 in Beverly Hills, California. To RSVP, please check here.
*****************
Cisco -3/7 article
New wearables revolutionize detection of health issues
by Stephanie Chan
April 17, 2017
(Also mentions iTBra)
**************
Cisco- 4/7 article
Maciej Kranz
(Vice President and General Manager
Corporate Strategic Innovation Group)
With Early Cancer Detection, IoT Saves More than Money—It Can Save Lives
Maciej Kranz
This week at the Internet of Things World Forum, we’ve been hearing a lot about the transformational value of the Internet of Things (IoT) across many industries – manufacturing, transportation, agriculture, smart cities, retail, and finance. So many new solutions are on display that help organizations either save or make money. But in healthcare, IoT can actually do more than that, it has the potential to save lives.
You may be thinking, “Of course—wearables, remote monitoring, performance tracking. These concepts have been around for a while now.” And yes, these technologies and devices are already working to improve health and fitness. One recent development, however, has really captured my attention because of its potential to help with early detection of breast cancer. That’s the idea behind the connected bra—dubbed the” iTBra” by its inventor, Rob Royea, CEO of Cyrcadia Health. With embedded temperature sensors, this new kind of wearable technology tracks changes in temperature in breast tissue over time. It uses machine learning and predictive analytics to identify and classify abnormal patterns that could indicate early stage breast cancer. And women will be glad to know that they just need to wear the iTBra for 2 to 12 hours once a month as they go about their daily activities—there’s no painful squashing or prodding or radiation involved.
The iTBra fits comfortably under virtually any normal bra and can transmit results to a smartphone.
This technology marks a vast improvement over traditional mammography, which generally doesn’t detect the presence of cancer until it is in Stage 3 or 4. It is also much more accurate than mammography, which produces a high number of both false-positive and false-negative results. Currently, more than 70 percent of biopsies that are done as a result of a suspicious mammogram turn out to be non-cancerous tissue. And in women with dense breast tissue, mammograms miss the presence of cancer more than 50 percent of the time. Because the iTBra relies on different detection technology, its false negative rate has so far been 17.3 percent for all tissue types—an improvement for all women, but especially for those with dense tissue.
Connected bra technology is many times more accurate than mammography in detecting the presence of cancer.
“Detected” is a new short documentary film sponsored by Cisco that shows the development of the iTBra, from the seed of an idea to its acceptance for clinical trials. The power of this documentary is not only about the ground-breaking idea itself, but also about the innovation process. I have been a keen observer and practitioner of innovation and co-innovation for years, and therefore I appreciate how the film realistically depicts the entrepreneurial struggle—a great idea, some false starts, some wrong turns. We also see Rob Royea’s grit and determination as he doggedly persists through obstacles, builds a coalition of the willing across the globe, and spreads his enthusiasm and passion about the project to people around him.
Rob Royea, right, discusses circuitry design with a development partner in Israel.
The connected bra idea is already so powerful by itself; but this is just a start. As Rob Royea says in the film, “What if you can screen three million people in Asia in a single year? What if you can create this mega database through the Internet, that can analyze how some people, versus others, have cancer?“
This is where IoT, in combination with the cloud, machine learning, and analytics capabilities, can truly become transformative. Mammograms—and the radiology expertise needed to interpret their results—are still out of reach for billions of women, especially in poor countries. Now, with inexpensive, non-invasive technology, you can now screen millions of women who have never had access to screening before. And in the process you can gather massive amounts of anonymized data that can help us research and hopefully better understand what factors contribute to a woman getting breast cancer in the first place. In a world where more than half-a-million women die from breast cancer each year, such connected IoT solutions can not only help cancer detection, but also cancer prevention.
The connected bra is just one of the reasons IoT in healthcare is especially exciting to me. Combined with rapid advances in areas ranging from bio- and DNA engineering, to robotics, prosthetics, and remote care, IoT is poised to dramatically improve many aspects of our lives—enhancing not only how long, but also how well we live. This is why I believe it is so important to rally behind entrepreneurs such as Rob Royea. We should support the efforts of current innovators and create incentives and programs for new ventures in the IoT healthcare field. Because in healthcare, the stakes are not just about efficiency or productivity; they’re about our lives.
*******************
Cisco -article 5/7
Detected: How IoT, Cloud, Wearables, and AI show hope in the fight against breast cancer
May 24, 2017
****************
Cisco article 6/7
AI creates breakthroughs in Alzheimer's and beyond
by Stephanie Chan
January 29, 2018
****************
Twitter Cisco post AI artificial intelligence is the future
Nov 1, 2018. Cisco @ Cisco
Analytics and automation are fueling an IT operations revolution. Are you ready? cs.co/6013Dhqft
—-Tweet: Cyrcadia Health Cyrcadia Asia create cloud based Core Lab Div Cyrcadia user base grows, it has the potential to be the world lgst database of breast prevention /treatment Data from the iTBra is communicated directly to the Cyrcadia's Core Lab for analysis by PC /smartphone app
***********************
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Tic toc tic toc ..,.
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
Lucky r u a women, and if so are you nervous about trying it, As in end result ?
My wife said she would have no problem trying it, as a matter fact if the clinical trial was here in St. Louis she would register for it.
I just asked Jim about European sales, Guess I’ll see if he responds?
used to ice race motocross early years, now I just ride those primitive technology machines Harley Davidson...;)... figured I’d kill myself on anything faster! I’ve sent Jim a request regarding the IT bra sale, but I haven’t heard anything yet, Sometimes he responds sometimes not. I’ve had several responses last couple years and that’s it. Honestly I’m surprise he responds at all, I wouldn’t.
Just had a post workout chocolate milkshake wish I had some Belgian chocolate in it, just used the old Hershey’s unsweetened cocoa powder, Raw eggs, honey and milk still good though...
One way to tell that circadian breast monitor is real is if they have the app to send to the analytical database center, If not it’s simply a show and tell product ???
The happy Frenchman...motorcycle riding in Europe is great.
(MO is full of good riding as well...!)
Well hopefully some news soon, but I believe Covid has slowed things down.
As far as research goes, “there’s more than one way to skin a cat”!
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
( Amazing how some people make comments about research when they obviously don’t even understand the product and the changes made)
(As Mentioned before, she’s been setting the lab up for the past three years getting ready for CBM data input and AI-ANN results)
Vinitha Sree
Director, “Analytics Core Lab”@ Cyrcadia Health, Inc.
Skills:
Cancer Research, Clinical Decision Support, Materials Science, Computer Aided Diagnosis, Matlab, Biomedical Engineering, Clinical Research, Image Processing, Life Sciences, Atherosclerosis, Data Mining, Signal Processing, Bioinformatics, Breast Imaging, Cancer, Diabetes Management, Research, Healthcare Management, Machine Learning, SPSS, Pattern Recognition
“Computer Methods and Programs in Biomedicine
Volume 197, December 2020, 105758
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device
Vinitha Sree”
Jim’s pretty easy to catch up with, find him at the Office 1325 Airmotive Way Suite 175 L Reno, NV.,
home Xxx xxxxx xxxxxxx, Reno, NV., & occasionally out sailing Lake Tahoe which he has a passion for.
Very personable individual.
FDA advances landmark policy changes to modernize mammography services and improve their quality
Today’s proposed amendments are part of the agency’s broader commitment to supporting “new innovations” and methods to prevent, detect and treat cancer. We are dedicated to working across the agency and with stakeholders to provide patients with tools and information to fight breast cancer effectively.”4-2019
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the
past...13
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
Checked with El Camino hospital clinical trial site, study still closed, did not check OS cancer Inst., but was open last Nov when I posted their reply.
Regardless I do not believe the initial investor groups have changed: which I have re-posted below.
Clinical trial: Well let's look at what we do know versus total speculation.
The majority if not all of the original investors are still invested.
RB investments, Reno angel group, and The Propell group are still invested.
Most interesting is that the propell group likes to invest in companies that could be disruptive technology.
The angel group has a target of $100 million potential market to qualify for their capital outlay.
El Camino has closed the IT bra enrollment, and OSCCC is still open for enrollment.
Indications are that the Cyrcadia Breast Monitor has shown 82% or better efficacy.
All The above I do know
So have they or have they not filed for FDA approval, they had mentioned in the past
that FDA submittal would occur simultaneously ?
How soon will they make any kind of press release ?
Will they sell the company or look for further large VC investor ?
These things I don't know.
One last thing I forgot to mention is that one of several criteria other than $100 Mill mkt opportunity was that the Reno angel groups investment with any company had to have a clear exit strategy, which was that
The start up company had to be sold or significant investment by a VC, in other words they wanted their share of the pie immediately.
All of the information above took several hours of investigating online.
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see !
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the Cyrcadia Breast Monitor -tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some Cyrcadia Breast Monitors...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Post# 27171
PHd cancer researcher perspective Hint: U may be induced to buy more shares!
Post# 27131 PPS it’s long,but conclusion: pps.22 or more (updated per above $.14 PPS)
Post#27094 Co marketing intent: the short “it’s happening”!
Post# 27061 Market size & Need: Summary-It’s Huge & Needed
Post# 26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$ (Insurance CO’s want this money saving technology)
Post #27037 Number of breast cancer cases & importance of early detection: “Your life may depend on it”.
Post#26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
Post#25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
iFlytec(Keda Xunfei) & Cyrcadia Health
Bloomberg Nov, 2017 iFlytec video (6 months after iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted saying...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley office”
Read between the lines, LLBO S/B trading above .05 cents per share.
****************
Whole post I posted on 5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Sent 5/14/20
Hi Jim,
Will you be explaining what has happened to Lifeline Biotechnologies percentage share ownership of about 45% of Cyrcadia Health to 30% ?
(As well as what has happened to the 15% equity)
I’m glad to see testing still on going at El Camino Hospital, hopefully
FDA will approve the changes soon.
Thank you Jim
Mike DeMunbrun
Investor
El Camino Hospital:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Services menu
* Clinical Trials
Phase: Pilot/Feasibility
Status: 1/2021 Recruiting
(pilot studies are not usually analytical trials designed to test a hypothesis (e.g., that the product performance exceeds that of a competitor). Instead, they usually focus on gathering data for use in optimizing the design of “subsequent clinical researchor device modifications.”)
—The purpose of this study is to determine if the Cyrcadia device can predict if a woman has breast cancer or benign breast tissue. The Cyrcadia device includes two adhesive patches with electrodes that are fitted over each breast. It collects data on the dynamic temperature changes in the breasts over time and transfers acquired data to a processing location which will return results to your physician. To determine the accuracy of this device, it will be tested on a group of women who have been scheduled for a breast biopsy due to a suspicious imaging test.
Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.
NCT Number
NCT02511301
Contact
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.
((Other endpoints of the study are:
* to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.
* to determine the optimal wear time for the Cyrcadia CBR™.
* to demonstrate substantial equivalent or improved results when applied to Cyrcadia original patient case study with identical ANN-advanced neural network analysis computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
Jan 29,2021
Post on
Interesting nurse Barb & Cyrcadia LLBO Board member( Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ) work at El Camino where the CMD formally iT Bra pilot study (reconfirming ANN -AI artificial intelligence modified algorithm) can improve end specificity results ...((“Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is building the largest breast data -data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve “specificity.”
)Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.) recognize the name !
Certainly sounds like as previously quoted by past researchers as Disruptive Technology...tic toc
Abstracts tying into each other, the noose tightens, the dice roll Sep, 2020
2020 Sep
Abstract:
“An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device”
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020 Dec.
excerpt: A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
((On Cyrcadia board: Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ))
2009
Abstract: “Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data”
excerpt: “Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer 2009”
Joanna M Y Tan et al. J Med Syst. 2009 Apr. Authors
Joanna M Y Tan 1 , E Y K Ng, Rajendra U Acharya, Louis G Keith, Jim Holmes
2006
Abstract: “The potential role of dynamic thermal analysis in breast cancer detection”
M Salhab et al. Int Semin Surg Oncol. 2006.
14: Salhab M, Al Sarakbi W, Mokbel K. The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol. 2005;2:8. doi: 10.1186/1477-7800-2-8. - DOI - PMC - PubMed
excerpt-
“The Future:
Dynamic thermal analysis of the breast is a safe, non invasive approach that seems to be sensitive for the early detection of breast cancer especially in young women where the conventional mammography is of limited value. Such a technology could become the initial breast screening test in pre-menopausal women and those who are classified as positive can then be selected for anatomical imaging with mammography, MRI and/or ultrasonography. “Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is build the largest breast data data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve specificity. Prospective multi-centre trials are then required to validate these promising observations.”
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
(From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
Done
PPS .14 ...Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
Checked with El Camino hospital clinical trial site, study still closed, did not check OS cancer Inst., but was open last Nov when I posted their reply.
Regardless I do not believe the initial investor groups have changed: which I have re-posted below.
Clinical trial: Well let's look at what we do know versus total speculation.
The majority if not all of the original investors are still invested.
RB investments, Reno angel group, and The Propell group are still invested.
Most interesting is that the propell group likes to invest in companies that could be disruptive technology.
The angel group has a target of $100 million potential market to qualify for their capital outlay.
El Camino has closed the IT bra enrollment, and OSCCC is still open for enrollment.
Indications are that the Cyrcadia Breast Monitor has shown 82% or better efficacy.
All The above I do know
So have they or have they not filed for FDA approval, they had mentioned in the past
that FDA submittal would occur simultaneously ?
How soon will they make any kind of press release ?
Will they sell the company or look for further large VC investor ?
These things I don't know.
One last thing I forgot to mention is that one of several criteria other than $100 Mill mkt opportunity was that the Reno angel groups investment with any company had to have a clear exit strategy, which was that
The start up company had to be sold or significant investment by a VC, in other words they wanted their share of the pie immediately.
All of the information above took several hours of investigating online.
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see !
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the Cyrcadia Breast Monitor -tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some Cyrcadia Breast Monitors...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Post# 27171
PHd cancer researcher perspective Hint: U may be induced to buy more shares!
Post# 27131 PPS it’s long,but conclusion: pps.22 or more (updated per above $.14 PPS)
Post#27094 Co marketing intent: the short “it’s happening”!
Post# 27061 Market size & Need: Summary-It’s Huge & Needed
Post# 26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$ (Insurance CO’s want this money saving technology)
Post #27037 Number of breast cancer cases & importance of early detection: “Your life may depend on it”.
Post#26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
Post#25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
iFlytec(Keda Xunfei) & Cyrcadia Health
Bloomberg Nov, 2017 iFlytec video (6 months after iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted saying...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley office”
Read between the lines, LLBO S/B trading above .05 cents per share.
****************
Whole post I posted on 5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Sent 5/14/20
Hi Jim,
Will you be explaining what has happened to Lifeline Biotechnologies percentage share ownership of about 45% of Cyrcadia Health to 30% ?
(As well as what has happened to the 15% equity)
I’m glad to see testing still on going at El Camino Hospital, hopefully
FDA will approve the changes soon.
Thank you Jim
Mike DeMunbrun
Investor
El Camino Hospital:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Services menu
* Clinical Trials
Phase: Pilot/Feasibility
Status: 1/2021 Recruiting
(pilot studies are not usually analytical trials designed to test a hypothesis (e.g., that the product performance exceeds that of a competitor). Instead, they usually focus on gathering data for use in optimizing the design of “subsequent clinical researchor device modifications.”)
—The purpose of this study is to determine if the Cyrcadia device can predict if a woman has breast cancer or benign breast tissue. The Cyrcadia device includes two adhesive patches with electrodes that are fitted over each breast. It collects data on the dynamic temperature changes in the breasts over time and transfers acquired data to a processing location which will return results to your physician. To determine the accuracy of this device, it will be tested on a group of women who have been scheduled for a breast biopsy due to a suspicious imaging test.
Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.
NCT Number
NCT02511301
Contact
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.
((Other endpoints of the study are:
* to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.
* to determine the optimal wear time for the Cyrcadia CBR™.
* to demonstrate substantial equivalent or improved results when applied to Cyrcadia original patient case study with identical ANN-advanced neural network analysis computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
Jan 29,2021
Post on
Interesting nurse Barb & Cyrcadia LLBO Board member( Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ) work at El Camino where the CMD formally iT Bra pilot study (reconfirming ANN -AI artificial intelligence modified algorithm) can improve end specificity results ...((“Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is building the largest breast data -data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve “specificity.”
)Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.) recognize the name !
Certainly sounds like as previously quoted by past researchers as Disruptive Technology...tic toc
Abstracts tying into each other, the noose tightens, the dice roll Sep, 2020
2020 Sep
Abstract:
“An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device”
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020 Dec.
excerpt: A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
((On Cyrcadia board: Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ))
2009
Abstract: “Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data”
excerpt: “Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer 2009”
Joanna M Y Tan et al. J Med Syst. 2009 Apr. Authors
Joanna M Y Tan 1 , E Y K Ng, Rajendra U Acharya, Louis G Keith, Jim Holmes
2006
Abstract: “The potential role of dynamic thermal analysis in breast cancer detection”
M Salhab et al. Int Semin Surg Oncol. 2006.
14: Salhab M, Al Sarakbi W, Mokbel K. The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol. 2005;2:8. doi: 10.1186/1477-7800-2-8. - DOI - PMC - PubMed
excerpt-
“The Future:
Dynamic thermal analysis of the breast is a safe, non invasive approach that seems to be sensitive for the early detection of breast cancer especially in young women where the conventional mammography is of limited value. Such a technology could become the initial breast screening test in pre-menopausal women and those who are classified as positive can then be selected for anatomical imaging with mammography, MRI and/or ultrasonography. “Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is build the largest breast data data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve specificity. Prospective multi-centre trials are then required to validate these promising observations.”
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
(From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
Done
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.
Nice 5 Mil share trade 1st min
Cyrcadia is a privately traded company, based in Reno, Nevada. Cyrcadia has achieved three patents through Lifeline Biotechnologies (LLBO), which is a publicly traded company that owns approximately 30% of Cyrcadia.
For further information, please contact Jim Holmes at jholmes@cyrcadiahealth.com
Our core science and the basis for our three patents is the discovery of the relationship between disruption of the body’s circadian body rhythms and tissue disruption. Prediction of the impact caused by Circadian rhythm disruption is the basis of the Circadian Health clinical trials. No one has developed a technology that competes with this core science. Many have validated our path of validation and discovery.
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.
Funny, the sore losers of the past Winds of loss Can only try to discredit a wonderful technology, One that could’ve saved my mothers life...So go on and call it garbage, if anything is garbage it’s GameStop. The Cyrcadia Breast Monitor CBM is the game...13 ;)
Mead r u seeing this, devine intervention
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.